From the Wires
BONESUPPORT Selected As A 2012 Red Herring Top 100 Global
By: PR Newswire
Dec. 6, 2012 09:31 AM
LUND, Sweden, Dec. 6, 2012 /PRNewswire/ -- BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that it has been selected as a Top 100 Winner for Red Herring's 2012 Global Award in recognition as a leader in innovation and technology among private companies from North America, Europe and Asia. Red Herring's Top 100 Global list has become a mark of distinction for identifying promising new companies and entrepreneurs.
"Choosing the companies with the strongest potential was by no means a small feat," said Alex Vieux, publisher and CEO of Red Herring. "After rigorous contemplation and discussion, we narrowed our list down from hundreds of Global candidates to the Top 100 Winners. We believe BONESUPPORT embodies the vision, drive and innovation that define a successful entrepreneurial venture. BONESUPPORT should be proud of its accomplishment, as the competition was the strongest it has ever been."
Red Herring's editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track record and standing of startups relative to their peers, allowing Red Herring to see past the "buzz" and make the list a valuable instrument of discovery and advocacy for the most promising new business models from around the world.
"This is a great distinction for BONESUPPORT as we continue to focus our efforts on global commercialization of our platform technology CERAMENT™," said Lloyd Diamond, CEO of BONESUPPORT. "This award will help to further build awareness of our innovative technology and I am pleased that we have been recognized in this way."
About Red Herring
CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery.
CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years and over forty-five pre-clinical, clinical and animal studies have been conducted. More than 4,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.
Latest Cloud Developer Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week